Drug Profile
Research programme: anticancer therapeutics - Institute of Microbial Chemistry/Mercian Corporation
Alternative Names: NBRI16716A; NBRI16716B; NBRI16716CLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Institute of Microbial Chemistry
- Developer Institute of Microbial Chemistry; Mercian
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in Japan